Results 51 to 60 of about 15,117 (209)
Lupus Science and Medicine, 2023 Objective To assess the efficacy of anifrolumab, a type-1 interferon receptor subunit-1 monoclonal antibody, in treating refractory cutaneous lupus erythematosus (CLE) and lupus non-specific mucocutaneous manifestations in patients with systemic lupus ...
Jun Kang, Aaron Bao
doaj +1 more source
Cancer complicating systemic lupus erythematosus--a dichotomy emerging from a nested case-control study [PDF]
, 2013 We determined whether any individual cancers are increased or decreased in a cohort of 595 patients with systemic lupus erythematosus (SLE) followed for up to 32 years at the University College London Hospitals Lupus Clinic, looking for any associated ...
Dey, D, Isenberg, DA, Kenu, E
core +1 more source
Systemic 5-fluorouracil induced lupus erythematosus: a review of the literature [PDF]
, 2019 Drug-induced subacute cutaneous lupus erythematosus (SCLE) is the most common subtype of drug-induced systemic lupus erythematosus and has been associated with more than 100 drugs.
Marsch, Amanda F, Shakhbazova, Anastasia
core
Successful Treatment of Systemic Lupus Erythematosus with Subcutaneous Immunoglobulin [PDF]
, 2016 The therapeutic efficacy of high-dose intravenous immunoglobulin in systemic lupus erythematosus (SLE) patients is well established. However, side effects might limit its use and lead to the consideration of therapeutic alternatives, such as the ...
Brasileiro, A +3 more
core +1 more source
Arthritis Care &Research, EarlyView.Objective We evaluated the role of 25‐hydroxyvitamin D (25[OH]D), prednisone, and other risk factors for bone mineral density (BMD) loss and osteoporosis in systemic lupus erythematosus (SLE). Methods We calculated the association between 25(OH)D levels and other potential risk factors and BMD measures (spine T scores) and osteoporosis (defined as a T ...
Nima Madanchi +4 more
wiley +1 more source
Semina: Ciências Agrárias, 2010 The objectives of this study were to do a survey of the autoimmune skin diseases and update the records regarding the occurrence of discoid lupus erythematosus in canine and feline populations attended at the Dermatology Service of the College of ...
Jéssica Correa Rodrigues +4 more
doaj +1 more source
Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus [PDF]
, 2012 Introduction: Cutaneous lupus erythematosus (CLE) is a chronic disease characterized by disfigurement and a relapsing course. Thalidomide has proven its efficacy in refractory cutaneous lupus disease, although it is not exempt from significant side ...
Cortés Hernández, Josefina +3 more
core +3 more sources
Clinical, Cosmetic and Investigational Dermatology, 2022 Wasin Saowaluksakul,1 Chutima Seree-aphinan,1 Suthinee Rutnin,1 Kochawan Boonyawat,2 Kumutnart Chanprapaph1 1Division of Dermatology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; 2Division of ...
Saowaluksakul W +4 more
doaj
A Randomized, Placebo‐Controlled Trial of Hydroxychloroquine in Incomplete Lupus
Arthritis &Rheumatology, EarlyView.Objective Patients with features of systemic lupus erythematosus (SLE) who do not fulfill classification criteria can be designated as incomplete lupus erythematosus (ILE). This condition includes individuals with a high risk of progression to SLE. Treatment of ILE may reduce symptoms, severity, and incidence of SLE.
Nancy J. Olsen +14 more
wiley +1 more source
SAGE Open Medical Case ReportsA 61-year-old female with systemic lupus erythematosus presented with refractory discoid lupus. Despite treatment with numerous immunosuppressive therapies, including prednisone, hydroxychloroquine and mycophenolate mofetil, her cutaneous lupus remained ...
Abdullah Ramadhan +3 more
doaj +1 more source